Naredi Nikita, Karunakaran Sandeep
Department of Obstetrics and Gynaecology, Assisted Reproductive Technology Centre, Army Hospital (R and R), New Delhi, India.
J Hum Reprod Sci. 2013 Oct;6(4):248-52. doi: 10.4103/0974-1208.126293.
Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic and potentially life-threatening disease process, which may occur in healthy young women undergoing controlled ovarian hyperstimulation for assisted reproduction. As the treatment is largely empirical, prevention forms the mainstay of management.
The present study was aimed to evaluate the effectiveness of intravenous (IV) calcium gluconate infusion in comparison to the dopamine agonist cabergoline (Cb2) in preventing OHSS in high risk patients undergoing assisted reproductive technique cycles.
It was a comparative study wherein the 202 high risk patients undergoing in vitro-fertilization over a period of 18 months after meeting the strict inclusion and the exclusion criteria, were randomly divided into two groups (98 subjects in Group I and 104 in Group II). Women in Group I were administered IV calcium gluconate while the remaining 104 received the dopamine agonist Cb2. The 104 patients belonging to Group II were started Cb2 0.5 mg/day from the day of ovulation trigger and continued until the next 8 days while the 98 high risk patients from Group I were infused with 10 ml of 10% calcium gluconate solution in 200 ml physiologic saline within 30 min of ovum pick up and continued thereafter on day 1, day 2 and day 3.
The occurrence of OHSS was seen in only nine patients (in the calcium infusion group, when compared with 16 patients (9.2% vs. 15.4%) who were administered Cb2, but it was not statistically significant. However, only one had severe OHSS in Group I, whereas two women were diagnosed as severe OHSS belonging to the Cb2 arm.
Our results document that calcium infusion can effectively prevent severe OHSS and decreases OHSS occurrence rates when used for high-risk patients, but does not suggest its superiority over Cb2. With comparable success rates, either of them can be employed as a preventive strategy for OHSS.
卵巢过度刺激综合征(OHSS)是一种医源性且可能危及生命的疾病过程,可能发生在接受辅助生殖控制性卵巢刺激的健康年轻女性身上。由于治疗主要是经验性的,预防是管理的主要支柱。
本研究旨在评估静脉输注葡萄糖酸钙与多巴胺激动剂卡麦角林(Cb2)相比,在接受辅助生殖技术周期的高危患者中预防OHSS的有效性。
这是一项对比研究,在18个月期间,202名符合严格纳入和排除标准的接受体外受精的高危患者被随机分为两组(第一组98名受试者,第二组104名)。第一组女性接受静脉输注葡萄糖酸钙,其余104名接受多巴胺激动剂Cb2。第二组的104名患者从触发排卵日开始每天服用0.5 mg Cb2,并持续至接下来的8天,而第一组的98名高危患者在取卵后30分钟内于200 ml生理盐水中输注10 ml 10%葡萄糖酸钙溶液,并在第1天、第2天和第3天继续输注。
仅9名患者出现OHSS(在钙输注组),与之相比,接受Cb2治疗的有16名患者(9.2%对15.4%),但差异无统计学意义。然而,第一组只有1例出现严重OHSS,而Cb2组有2名女性被诊断为严重OHSS。
我们的结果表明,钙输注可有效预防高危患者的严重OHSS并降低OHSS发生率,但并不表明其优于Cb2。成功率相当,二者均可作为OHSS的预防策略。